{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:47:16Z","timestamp":1785278836529,"version":"3.55.0"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI14\/00242"],"award-info":[{"award-number":["ICI14\/00242"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01321"],"award-info":[{"award-number":["PI16\/01321"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["INT15\/00112"],"award-info":[{"award-number":["INT15\/00112"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI17\/00233"],"award-info":[{"award-number":["FI17\/00233"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["18CEE002"],"award-info":[{"award-number":["18CEE002"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["SLT002\/16\/00183"],"award-info":[{"award-number":["SLT002\/16\/00183"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00241","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T04:34:52Z","timestamp":1573187692000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Immune-Monitoring Disease Activity in Primary Membranous Nephropathy"],"prefix":"10.3389","volume":"6","author":[{"given":"Paolo","family":"Cravedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Angeletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c0lex","family":"Fav\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cantarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.ajkd.2010.01.008","article-title":"The pathogenesis of idiopathic membranous nephropathy: a 50-years odyssey","volume":"56","author":"Glassock","year":"2010","journal-title":"Am J Kidney Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ki.1983.170","article-title":"Pathologic differentiation between lupus and non-lupus membranous glomerulopathy","volume":"24","author":"Jennette","year":"1983","journal-title":"Kidney Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrneph.2013.125","article-title":"Treatment of idiopathic membranous nephropathy","volume":"9","author":"Hofstra","year":"2013","journal-title":"Nat Rev Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/phar.1575","article-title":"Overview of current and alternative therapies for idiopathic membranous nephropathy","volume":"35","author":"Tran","year":"2015","journal-title":"Pharmacotherapy."},{"key":"B5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12882-017-0525-6","article-title":"Factors affecting the long-term outcomes of idiopathic membranous nephropathy","volume":"18","author":"Huh","year":"2017","journal-title":"BMC Nephrol."},{"key":"B6","first-page":"697","article-title":"The clinical course of idiopathic membranous nephropathy","volume":"48","author":"Erwin","year":"1973","journal-title":"Mayo Clin Proc."},{"key":"B7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S0272-6386(12)80685-8","article-title":"The recurrence of recurrent membranous glomerulopathy in a renal transplant recipient: case report and literature review","volume":"24","author":"Josephson","year":"1994","journal-title":"Am J Kidney Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1056\/NEJMoa013036","article-title":"Risk of renal allograft loss from recurrent glomerulonephritis","volume":"347","author":"Briganti","year":"2002","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1600-6143.2011.03903.x","article-title":"The pathology and clinical features of early recurrent membranous glomerulonephritis","volume":"12","author":"Rodriguez","year":"2012","journal-title":"Am J Transplant."},{"key":"B11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.kint.2016.08.030","article-title":"Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation","volume":"91","author":"Cosio","year":"2017","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12882-018-1025-z","article-title":"A large, international study on post-transplant glomerular diseases: the TANGO project","volume":"19","author":"Uffing","year":"2018","journal-title":"BMC Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1093\/ndt\/gfu333","article-title":"Membranous nephropathy transplanted in the donor kidney: observations of resolving glomerulopathy in serial allograft biopsies","volume":"29","author":"Mirza","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1111\/ctr.12847","article-title":"Membranous nephropathy in the kidney allograft","volume":"30","author":"Filippone","year":"2016","journal-title":"Clin Transplant."},{"key":"B15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3181\/00379727-100-24736","article-title":"Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions","volume":"100","author":"Heymann","year":"1959","journal-title":"Proc Soc Exp Biol Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1172\/JCI109987","article-title":"A new role for complement in experimental membranous nephropathy in rats","volume":"66","author":"Salant","year":"1980","journal-title":"J Clin Invest."},{"key":"B17","first-page":"57","article-title":"Distribution of IgG subclasses in membranous nephropathy","volume":"58","author":"Doi","year":"1984","journal-title":"Clin Exp Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000185234","article-title":"Glomerular deposition of C4 cleavage fragment (C4d) and C4-binding protein in idiopathic membranous glomerulonephritis","volume":"51","author":"Kusunoki","year":"1989","journal-title":"Nephron."},{"key":"B19","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.4049\/jimmunol.154.7.3437","article-title":"Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis","volume":"154","author":"Quigg","year":"1995","journal-title":"J Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.semnephrol.2013.08.004","article-title":"The role of complement in membranous nephropathy","volume":"33","author":"Ma","year":"2013","journal-title":"Semin Nephrol."},{"key":"B21","first-page":"455","article-title":"Analytical pathology. III. New observations on the pathogenesis of glomerulonephritis, lipid nephrosis, periarteritis nodosa, and secondary amyloidosis in man","volume":"32","author":"Mellors","year":"1956","journal-title":"Am J Pathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/ajcp\/32.2.109","article-title":"The fine structure of the glomerulus in membranous glomerulonephritis (lipoid nephrosis) in adults","volume":"32","author":"Movat","year":"1959","journal-title":"Am J Clin Pathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.2215\/CJN.06230614","article-title":"Molecules great and small: the complement system","volume":"10","author":"Mathern","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(04)17142-0","article-title":"Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies","volume":"364","author":"Debiec","year":"2004","journal-title":"Lancet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMc1011678","article-title":"PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy","volume":"364","author":"Debiec","year":"2011","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J Clin Invest."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e104936","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PLoS ONE."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0138841","DOI":"10.1371\/journal.pone.0138841","article-title":"Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of japanese patients with idiopathic membranous nephropathy","volume":"10","author":"Iwakura","year":"2015","journal-title":"PLoS ONE."},{"key":"B32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/modpathol.2016.32","article-title":"THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod Pathol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet."},{"key":"B35","first-page":"328","article-title":"CD20-positive infiltrates in human membranous glomerulonephritis","volume":"18","author":"Cohen","year":"2005","journal-title":"J Nephrol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1159\/000327611","article-title":"Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study","volume":"33","author":"Cravedi","year":"2011","journal-title":"Am J Nephrol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz086","article-title":"Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy","author":"Barrett","year":"2019","journal-title":"Nephrol Dial Transplant."},{"key":"B38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cca.2019.01.015","article-title":"Urine markers of renal tubular injury in idiopathic membranous nephropathy: a cross sectional study","volume":"492","author":"An","year":"2019","journal-title":"Clin Chim Acta."},{"key":"B41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Non-invasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1681\/ASN.2017020178","article-title":"PLA2R and THSD7A: disparate paths to the same disease?","volume":"28","author":"Beck","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"j Am Soc Nephrol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.kint.2018.10.024","article-title":"Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy","volume":"95","author":"Zaghrini","year":"2019","journal-title":"Kidney Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1136\/jclinpath-2019-205852","article-title":"Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy","volume":"72","author":"Zhang","year":"2019","journal-title":"J Clin Pathol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0304-4165(02)00319-7","article-title":"The mannose receptor family","volume":"1572","author":"East","year":"2002","journal-title":"Biochim Biophys Acta."},{"key":"B47","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1074\/jbc.271.1.250","article-title":"Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2","volume":"271","author":"Zvaritch","year":"1996","journal-title":"J Biol Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0014-5793(00)01848-2","article-title":"Identification of group X secretory phospholipase A(2) as a natural ligand for mouse phospholipase A(2) receptor","volume":"478","author":"Yokota","year":"2000","journal-title":"FEBS Lett."},{"key":"B49","doi-asserted-by":"publisher","first-page":"C1102","DOI":"10.1152\/ajpcell.00608.2001","article-title":"Presence of the M-type sPLA(2) receptor on neutrophils and its role in elastase release and adhesion","volume":"283","author":"Silliman","year":"2002","journal-title":"Am J Physiol Cell Physiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"8963","DOI":"10.1074\/jbc.270.15.8963","article-title":"The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization","volume":"270","author":"Ancian","year":"1995","journal-title":"J Biol Chem."},{"key":"B51","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"102308","DOI":"10.1016\/j.jaut.2019.102308","article-title":"Autoantigens PLA2R and THSD7A in membranous nephropathy share a common epitope motif in the N-terminal domain","volume":"2019","author":"Fresquet","year":"2019","journal-title":"J Autoimmun."},{"key":"B54","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(79)92118-4","article-title":"Strong association between idiopathic membranous nephropathy and HLA-DRW3","volume":"2","author":"Klouda","year":"1979","journal-title":"Lancet."},{"key":"B55","first-page":"35","article-title":"Familial membranous nephropathy","volume":"11","author":"Scolari","year":"1998","journal-title":"J Nephrol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1681\/ASN.2012080771","article-title":"Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy","volume":"24","author":"Lv","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2215\/CJN.05310513","article-title":"HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy","volume":"9","author":"Bullich","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/gene.2014.50","article-title":"PLA2R-associated membranous glomerulopathy is modulated by common variants in PLA2R1 and HLA-DQA1 genes","volume":"15","author":"Saeed","year":"2014","journal-title":"Genes Immun."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1093\/ndt\/gfv399","article-title":"PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians","volume":"31","author":"Ramachandran","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"B61","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/ndt\/gfw001","article-title":"Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies","volume":"32","author":"Sekula","year":"2017","journal-title":"Nephrol Dial Transplant."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1681\/ASN.2016020114","article-title":"MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy","volume":"28","author":"Cui","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1681\/ASN.2016060644","article-title":"HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-related membranous nephropathy","volume":"28","author":"Le","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2018.06.005","article-title":"HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy","volume":"94","author":"Wang","year":"2018","journal-title":"Kidney Int."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1681\/ASN.2013060576","article-title":"Can genetics risk-stratify patients with membranous nephropathy?","volume":"24","author":"Bomback","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1681\/ASN.2017030283","article-title":"Genetic complexities of the HLA region and idiopathic membranous nephropathy","volume":"28","author":"Mladkova","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/ndt\/gfs439","article-title":"Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy","volume":"28","author":"Svobodova","year":"2013","journal-title":"Nephrol Dial Transplant."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/ki.2015.310","article-title":"Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy","volume":"88","author":"Ramachandran","year":"2015","journal-title":"Kidney Int."},{"key":"B71","doi-asserted-by":"publisher","first-page":"143274","DOI":"10.1155\/2014\/143274","article-title":"Antiphospholipase A(2) receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy","volume":"2014","author":"Behnert","year":"2014","journal-title":"J Immunol Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1309\/AJCP8QMOY5GLRSFP","article-title":"Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study","volume":"142","author":"Timmermans","year":"2014","journal-title":"Am J Clin Pathol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/ckj\/sfw121","article-title":"Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy","volume":"10","author":"Jullien","year":"2017","journal-title":"Clin Kidney J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ckj\/sfy005","article-title":"Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy","volume":"12","author":"Rodas","year":"2019","journal-title":"Clin Kidney J."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ekir.2017.09.001","article-title":"Temporal association between PLA2R antibodies and clinical outcomes in primary membranous nephropathy","volume":"3","author":"Ramachandran","year":"2018","journal-title":"Kidney Int Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ki.2010.34","article-title":"Membranous nephropathy: recent travels and new roads ahead","volume":"77","author":"Beck","year":"2010","journal-title":"Kidney Int."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-phospholipase A2 receptor antibody in membranous nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.autrev.2015.10.004","article-title":"Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)","volume":"15","author":"Radice","year":"2016","journal-title":"Autoimmun Rev."},{"key":"B83","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000494662","article-title":"Antibodies against M-type phospholipase A2 receptor may predict treatment response and outcome in membranous nephropathy","volume":"48","author":"Qu","year":"2018","journal-title":"Am J Nephrol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2215\/CJN.05140512","article-title":"Association of epitope spreading of antiglomerular basement membrane antibodies and kidney injury","volume":"8","author":"Chen","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.imlet.2014.11.001","article-title":"B cell epitope spreading: mechanisms and contribution to autoimmune diseases","volume":"163","author":"Cornaby","year":"2015","journal-title":"Immunol Lett."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B89","first-page":"75","article-title":"Two-color analysis of lymphocyte subpopulations in patients with nephrotic syndrome due to membranous nephropathy","volume":"38","author":"Ozaki","year":"1992","journal-title":"Clin Nephrol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/147323001103900111","article-title":"Correlation between B lymphocyte abnormality and disease activity in patients with idiopathic membranous nephropathy","volume":"39","author":"Wang","year":"2011","journal-title":"J Int Med Res."},{"key":"B91","first-page":"70","article-title":"T cell subset alterations in idiopathic glomerulonephritis","volume":"50","author":"Cagnoli","year":"1982","journal-title":"Clin Exp Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000167547","article-title":"Prognostic value of T lymphocyte subset ratio in idiopathic membranous nephropathy","volume":"8","author":"Zucchelli","year":"1988","journal-title":"Am J Nephrol."},{"key":"B93","first-page":"176","article-title":"Impaired lymphocyte and suppressor cell function in minimal change nephropathy, membranous nephropathy and focal glomerulosclerosis","volume":"22","author":"Taube","year":"1984","journal-title":"Clin Nephrol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000058401","article-title":"Predominance of type-2 immune response in idiopathic membranous nephropathy. Cytoplasmic cytokine analysis","volume":"91","author":"Hirayama","year":"2002","journal-title":"Nephron."},{"key":"B95","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/ndt\/gfg572","article-title":"Up-regulated interleukin-4 production by peripheral T-helper cells in idiopathic membranous nephropathy","volume":"19","author":"Masutani","year":"2004","journal-title":"Nephrol Dial Transplant."},{"key":"B96","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1523-1755.2005.00415.x","article-title":"Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy","volume":"68","author":"Kuroki","year":"2005","journal-title":"Kidney Int."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.autrev.2016.02.014","article-title":"New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature","volume":"15","author":"Roccatello","year":"2016","journal-title":"Autoimmun Rev."},{"key":"B99","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1681\/ASN.2006101143","article-title":"Regulatory T cells and T cell depletion: role of immunosuppressive drugs","volume":"18","author":"Noris","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/ni.1818","article-title":"Regulatory T cells exert checks and balances on self tolerance and autoimmunity","volume":"11","author":"Wing","year":"2010","journal-title":"Nat Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet."},{"key":"B103","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2215\/CJN.05231008","article-title":"Rituximab therapy for membranous nephropathy: a systematic review","volume":"4","author":"Bomback","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nri.2017.24","article-title":"Altered B cell signalling in autoimmunity","volume":"17","author":"Rawlings","year":"2017","journal-title":"Nat Rev Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40120-018-0101-4","article-title":"Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders","volume":"7","author":"Lebrun","year":"2018","journal-title":"Neurol Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.vaccine.2005.08.058","article-title":"Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination","volume":"24","author":"Bauer","year":"2006","journal-title":"Vaccine."},{"key":"B108","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.humimm.2008.10.013","article-title":"Peripheral blood B cells producing donor-specific HLA antibodies in vitro","volume":"70","author":"Han","year":"2009","journal-title":"Hum Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1111\/j.1600-6143.2011.03982.x","article-title":"A NOVel ELISPOT assay to quantify HLA-specific B cells in HLA-immunized individuals","volume":"12","author":"Heidt","year":"2012","journal-title":"Am J Transplant."},{"key":"B110","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/ki.2015.205","article-title":"Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation","volume":"88","author":"Lucia","year":"2015","journal-title":"Kidney Int."},{"key":"B111","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/ajt.15055","article-title":"Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation","volume":"19","author":"Luque","year":"2019","journal-title":"Am J Transplant."},{"key":"B112","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jim.2018.07.011","article-title":"A multicolour HLA-specific B-cell FluoroSpot assay to functionally track circulating HLA-specific memory B cells","volume":"462","author":"Luque","year":"2018","journal-title":"J Immunol Methods."},{"key":"B113","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000368589","article-title":"Rituximab in primary membranous nephropathy: first-line therapy, why not?","volume":"128","author":"Cravedi","year":"2014","journal-title":"Nephron Clin Pract."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00241\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T16:35:17Z","timestamp":1695400517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00241\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":113,"alternative-id":["10.3389\/fmed.2019.00241"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00241","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"article-number":"241"}}